Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olvimulogene nanivacirepvec - Genelux Corporation

Next Previous
X
Search
Drug Profile

Olvimulogene nanivacirepvec - Genelux Corporation

Alternative Names: GL-ONC1; GLV-1h68; Olvi-Vec - Genelux Corporation

Latest Information Update: 08 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genelux Corporation
  • Developer Genelux Corporation; Memorial Sloan-Kettering Cancer Center; Newsoara Biopharma
  • Class Antineoplastics; Diagnostic agents; Imaging agents; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Non-small cell lung cancer
  • Phase I/II Small cell lung cancer
  • No development reported Head and neck cancer; Malignant pleural effusion; Solid tumours

Most Recent Events

  • 24 Oct 2024 Genelux completes a phase I trial for Malignant pleural effusion in USA (Intrapleural) (NCT01766739)
  • 26 Sep 2024 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06463665)
  • 31 Jul 2024 Genelux Corporation plans a phase II trial for Non-small cell lung cancer (Combination Therapy, Recurrent, Second line therapy or grater) in July 2024 (NCT06463665)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top